Retractable Technologies (RVP)
XASE:RVP
Want to see RVP full AI Analyst Report?
RVP Stock Chart & Stats
$0.73
>-$0.01(-0.49%)
At close: 4:00 PM EST
$0.73
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$0.60 - $1.14
Previous CloseN/A
Volume39.25K
Average Volume (3M)153.51K
Market Cap
$20.95M
Enterprise Value$18.48M
Total Cash (Recent Filing)$35.62M
Total Debt (Recent Filing)$916.05K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding29,937,159
10 Day Avg. Volume341,920
30 Day Avg. Volume153,511
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)0.31
Price to Sales (P/S)0.60
P/FCF Ratio-3.04
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue0.50
Enterprise Value/Gross Profit251.18
Enterprise Value/Ebitda11.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity gives the company durable financial flexibility to withstand ongoing operating losses and access capital if needed. Over a 2–6 month horizon this reduces near-term solvency risk and preserves options for restructuring or investment without immediate refinancing pressure.
Specialized Safety-device Product NicheA focused portfolio of safety-engineered syringes addresses a regulatory and clinical need that supports persistent demand. This product specialization creates recurring per-unit revenue, procurement relationships with healthcare buyers, and a defensible position against commoditized suppliers over multiple quarters.
Top-line And International Growth In 2025Meaningful 2025 revenue growth and a 64% jump internationally indicate the business can expand beyond a domestic normalization cycle. Geographic diversification and demonstrated ability to grow shipments provide a structural avenue to rebuild scale and absorb fixed costs over the medium term.
Bears Say
Persistent Losses And Margin DeteriorationSustained negative gross and net margins reflect structural pricing or cost disadvantages and an inability to cover fixed costs. Continued margin deficits erode equity and make profitable scale elusive unless addressed by pricing, mix, or cost transformation, threatening long-term viability if unresolved.
Negative Operating And Free Cash FlowOngoing cash burn and a low cash balance constrain runway and increase dependence on external financing or asset sales. Over a multi-month horizon this limits the company's ability to invest in growth, meet obligations, or execute strategic restructuring without dilutive or costly capital raises.
Tariff Exposure Driving Elevated Operating CostsLarge, persistent tariff charges materially inflate COGS and compress margins. This structural trade-policy risk can persist across quarters, forcing supply-chain changes, higher prices, or margin sacrifice; each option undermines competitiveness or profitability absent strategic remediation.
Retractable Technologies News
RVP FAQ
What was Retractable Technologies’s price range in the past 12 months?
Retractable Technologies lowest stock price was $0.60 and its highest was $1.14 in the past 12 months.
What is Retractable Technologies’s market cap?
Retractable Technologies’s market cap is $20.95M.
When is Retractable Technologies’s upcoming earnings report date?
Retractable Technologies’s upcoming earnings report date is Aug 17, 2026 which is in 62 days.
How were Retractable Technologies’s earnings last quarter?
Retractable Technologies released its earnings results on May 18, 2026. The company reported -$0.143 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.143.
Is Retractable Technologies overvalued?
According to Wall Street analysts Retractable Technologies’s price is currently Overvalued.
Does Retractable Technologies pay dividends?
Retractable Technologies does not currently pay dividends.
What is Retractable Technologies’s EPS estimate?
Retractable Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Retractable Technologies have?
Retractable Technologies has 29,937,159 shares outstanding.
What happened to Retractable Technologies’s price movement after its last earnings report?
Retractable Technologies reported an EPS of -$0.143 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.343%.
Which hedge fund is a major shareholder of Retractable Technologies?
Currently, no hedge funds are holding shares in RVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Retractable Technologies
Retractable Technologies, Inc. is a medical device company focused on the innovation, production, and sale of secure medical instruments, predominantly syringes, for the healthcare sector. Their reach extends across the United States, the broader North and South American continents, and other international territories. The company's diverse product range includes a variety of safety-engineered items such as VanishPoint insulin, tuberculin, and allergy antigen syringes, as well as Patient Safe syringes and Luer Caps. They also offer small diameter tube adapters, blood collection tube holders, allergy trays, and IV safety catheters. Further offerings feature VanishPoint blood collection sets, EasyPoint needles, and VanishPoint autodisable syringes. Distribution of these products occurs through a combination of general and specialized distributors, international partners, and a dedicated direct sales network. Founded in 1994, the company's main operations are headquartered in Little Elm, Texas.
Technical Analysis
Ownership Overview
55.66% Insiders
2.55% Mutual Funds
2.76% Other Institutional Investors
37.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---